Hyperprolactinemia is often a facet outcome of dopamine antagonists as blockade of D2 receptors within the tuberoinfundibular pathway results in enhanced plasma levels of prolactin due to enhanced secretion by lactotrophs while in the anterior pituitary. Employing this medicine with any of the su